Comment
doi: 10.1016/S1470-2045(19)30397-3.
NEJ026 trial: progression-free survival benefit is not enough
Affiliations
- PMID: 31267962
- DOI: 10.1016/S1470-2045(19)30397-3
Item in Clipboard
Comment
NEJ026 trial: progression-free survival benefit is not enough
Lancet Oncol.
2019 Jul.
No abstract available
Comment in
-
NEJ026 trial: progression-free survival benefit is not enough - Author's reply.Lancet Oncol. 2019 Jul;20(7):e345. doi: 10.1016/S1470-2045(19)30425-5. Lancet Oncol. 2019. PMID: 31267963 No abstract available.
Comment on
-
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
